Narratives

What's New

Your Valuation

Global Community

Our community narratives are driven by numbers and valuation.

Author Program NEW

Global Weekly Picks

Optimi Health

Lou_Basenese

Community Contributor

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Optimi Health already makes and ships controlled psychedelic medicines to paying clinics, while most rivals are still waiting for approvals. The story hinges on whether a real, insured market can scale fast enough to fill its underused factory—before funding and rule changes become a problem.

View narrative

US$11

57.5% undervalued

2.8k

Novo Nordisk

WealthAP

Community Contributor

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

31 Dec 2025 For shareholders of Novo Nordisk (NVO) , the past three years have been a masterclass in value creation. High margins, infinite demand, and a virtual monopoly in the obesity market drove the stock to record highs.

View narrative

DKK 407.77

21.4% undervalued

10.00%

Revenue growth p.a.

Zoetis

ValueInvestingSubstack

Community Contributor

Zoetis down -50% over the past year

Zoetis makes medicines for pets and farm animals, but a sharp slowdown in its US pet business recently rattles investors and raises questions about how durable demand really is. The story hinges on whether its long track record of steady pricing and buybacks can keep the business resilient—or whether debt, product concentration, and copycat drugs start to bite.

View narrative

US$92.92

18.9% undervalued

4.06%

Revenue growth p.a.

1.9k

Centrus Energy

CentryResearch

Community Contributor

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Nuclear power is back in the spotlight as data centers and AI push demand for reliable electricity, but a lesser-known fuel shortage could slow down the next wave of new reactors. One U.S. supplier sits close to this choke point, while many reactor builders may be forced to wait until the fuel supply catches up.

View narrative

US$190

13.7% undervalued

24.82%

Revenue growth p.a.

2.8k

Treasury Wine Estates

Is TWE Aging Well?

At A$7.072 per share, Treasury Wine Estates (ASX: TWE) appears reasonably valued, although the assessment relies on earnings recovering during the second half of FY26. TWE reported first-half revenue of A$1.30 billion, EBITS of A$236.4 million and underlying earnings of 15.9 cents per share.Read more

AU$7.07

33.1% undervalued

Jamesiskindacool's

Fair Value

Profit Margin

10.83%

Future PE

17.7x

Price in 2031

AU$9.92

Netcall

⚡ Two-Minute Drill: Netcall PLC - This £200M AI Stock Is Already Running the NHS

This UK small-cap is already deploying AI agents inside hospitals, councils and banks—automating everything from patient bookings to council tax enquiries. The market still values it like a boring workflow software company.Read more

UK£2.17

45.6% undervalued

European_Hidden_Gem_Stocks's

Fair Value

Revenue

23.47% p.a.

Profit Margin

4.67%

Future PE

83.88x

Price in 2031

UK£3.4

LVMH Moët Hennessy - Louis Vuitton Société Européenne

The Luxury Titan Mispriced by a Short‑Sighted Market

LVMH is the world’s largest luxury group — but the market isn’t treating it like one right now. The numbers tell a very clear story: the stock is priced as if the company’s golden era is over , while the fundamentals suggest the opposite.Read more

€680

32.1% undervalued

JH7's

Fair Value

Revenue

17.11% p.a.

Profit Margin

13.46%

Future PE

21.07x

Price in 2031

€1.02k

Rezolve AI

⚡ Two-Minute Drill: Rezolve AI - The AI That Doesn't Recommend Products. It Buys Them.

Everyone talks about AI helping people shop. This company wants AI to finish the purchase.Read more

US$80.78

97.2% undervalued

European_Hidden_Gem_Stocks's

Fair Value

Profit Margin

19%

Future PE

21.08x

Price in 2031

US$128.27

Saudi Ground Services

Saudi Ground Services revenue will rise by nearly 40%

I. Executive Summary and Signal The central thesis currently priced into the market is not the company's weakness, but the erosion of its monopoly.Read more

ر.س45

38.0% undervalued

Valtersa's

Fair Value

Revenue

39.89% p.a.

Profit Margin

13.46%

Future PE

14.22x

Price in 2029

ر.س76.1

Kuros Biosciences

How a Mispriced Medtech Engine is Disrupting $5,000 Bone Graft Giants.

Wall Street and retail investors routinely misprice Kuros Biosciences by lumping it into the speculative, cash-burning biotech basket. In reality, Kuros has transformed into a high-margin Medtech commercial powerhouse delivering ~80%+ YoY sales growth with ~80%+ Gross Margins and expanding operating profitability.Read more

US$342.18

92.5% undervalued

AnimalDoctorKwon's

Fair Value

Revenue

62% p.a.

Profit Margin

50%

Future PE

20x

Price in 2031

US$478.36

Woodside Energy Group

Does WDS Have More in the Tank?

At A$36.602 per share, Woodside Energy Group (ASX: WDS) appears reasonably valued based on its existing operations and near-term production growth. Woodside reports in US dollars and recorded 2025 operating revenue of US$12.9 billion, underlying profit of US$2.65 billion and earnings of US$1.43 per share.Read more

AU$36.6

11.6% undervalued

Jamesiskindacool's

Fair Value

Revenue

9.8% p.a.

Profit Margin

20.93%

Future PE

15.8x

Price in 2031

AU$51.34

Kartoon Studios

Kartoon Studios just Banked $39.2 Million.. So, Why is TOON Still Trading Below Cash?

Kartoon Studios announced approximately $78.5 million in litigation settlements—an enormous figure beside the company’s recent market value. For a moment, the story sounds easy: a small company wins a large settlement, receives the money, and the stock catches up.Read more

US$0.48

20.8% overvalued

DaneDruss's

Fair Value

I use a conservative cash-runway approach because Kartoon Studios does not yet have reliable positive earnings to support a P/E valuation. The company reported more than $40 million in cash and no debt as of June 30, 2026. I deduct approximately $11.7 million, representing one year of operating cash use annualized from Q1 2026, then divide the remaining $28.3 million by approximately 59.1 million basic shares. This produces a fair-value anchor of about $0.48 per share. This is not a liquidation value or earnings forecast. It assigns no value to unreceived settlement proceeds, warrant proceeds, retained intellectual property, or execution upside, while potential dilution remains a material risk. The estimate should be revised when the next quarterly filing verifies cash, liabilities, operating burn, and share count.

ASML Holding

ASML Will Reign as the Kingpin of the Semiconductor Supply Chain

ASML makes the one type of chipmaking machine that advanced chips can’t be built without, putting it at the center of the AI and high-end electronics boom. But that power comes with big dependencies—politics, a few key customers, and whether the next wave of machines is worth the cost.Read more